Alana Weinstein on Muck Rack

Alana Weinstein

As seen in: Nature, The Journal of Clinical Investigation

Get in touch with Alana

Contact Alana, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer

|
By Xiaolin Zhu, Tatyanah Farsh, Daniel C Vis, Ivan Yu, Daniel J Vis, Haolong Li, Tianyi Liu, Martin Sjöström, Raunak Shrestha, Jeroen Kneppers, Tesa M. Severson, Meng Zhang, Arian Lundberg, Alana Weinstein, Adam Foye, Niven Mehra, Rahul Aggarwal, Thaidy Moreno Rodriguez
| The Journal of Clinical Investigation
Abstract Introduction Metastatic castration-resistant prostate cancer (mCRPC) is the lethal form of prostate cancer (PCa) (1). Androgen receptor signaling inhibitors (ARSIs), such as abiraterone and enzalutamide, have improved outcomes for patients with mCRPC and hormone-sensitive prostate cancer (HSPC) (1). However, PCa invariably develops resistance to ARSIs, leaving patients with limited treatment options following disease progression (2).
Open in Who Shared Issue with article?

Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer - Nature Genetics

|
By Shuang G. Zhao, Stanley Zhou, Raunak Shrestha, Thaidy Moreno-Rodriguez, Arian Lundberg, Alana Weinstein, Martin Sjöström, Meng Zhang, Haolong Li, Kyle T Helzer, Yue Shi, Scott M. Dehm, Joshua Lang, Joshi J. Alumkal, Rahul Aggarwal, Wilbert Zwart, Eric Small, David Quigley Verified, Hansen H. He
| Nature Verified
Abstract The impact of variations in the three-dimensional structure of the genome has been recognized, but solid cancer tissue studies are limited. Here, we performed integrated deep Hi-C sequencing with matched whole-genome sequencing, whole-genome bisulfite sequencing, 5-hydroxymethylcytosine (5hmC) sequencing and RNA sequencing across a cohort of 80 biopsy samples from patients with metastatic castration-resistant prostate cancer.
Open in Who Shared Issue with article?

Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity - Nature Communications

|
By Ya-Mei Hu, Tomasz Beer, Rahul Aggarwal, Yuzhuo Wang, Jiaoti Huang, Peter Nelson, Christopher Wong, Alana Weinstein, Vlado Uzunangelov, Josh Stuart, George Thomas, Felix Feng, Eric Small, Joel A. Yates, Zheng Xia
| Nature Verified
Abstract The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent enza clinical resistance mechanisms have been described, including lineage plasticity in which the tumors manifest reduced dependency on the AR.
Open in Who Shared Issue with article?
See all 7 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified